Essex Investment Management Co. LLC Grows Stake in MediWound Ltd. (NASDAQ:MDWD)

Essex Investment Management Co. LLC increased its holdings in MediWound Ltd. (NASDAQ:MDWD) by 30.7% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 148,949 shares of the biopharmaceutical company’s stock after acquiring an additional 35,012 shares during the quarter. Essex Investment Management Co. LLC’s holdings in MediWound were worth $2,651,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in MDWD. State Street Corp raised its position in shares of MediWound by 219.6% during the 3rd quarter. State Street Corp now owns 66,258 shares of the biopharmaceutical company’s stock valued at $1,197,000 after buying an additional 45,529 shares in the last quarter. Barclays PLC increased its stake in MediWound by 311.3% in the third quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company’s stock valued at $202,000 after acquiring an additional 8,449 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in MediWound during the third quarter valued at about $212,000. R Squared Ltd bought a new stake in MediWound during the fourth quarter worth about $32,000. Finally, Yelin Lapidot Holdings Management Ltd. boosted its holdings in shares of MediWound by 13.4% in the 4th quarter. Yelin Lapidot Holdings Management Ltd. now owns 851,361 shares of the biopharmaceutical company’s stock worth $15,154,000 after purchasing an additional 100,618 shares in the last quarter. Institutional investors own 46.83% of the company’s stock.

MediWound Trading Up 4.4 %

NASDAQ MDWD opened at $16.93 on Monday. The firm has a market cap of $182.61 million, a PE ratio of -5.84 and a beta of 0.82. MediWound Ltd. has a 1-year low of $12.78 and a 1-year high of $24.00. The stock has a 50-day moving average of $18.06 and a 200-day moving average of $17.63.

Analyst Ratings Changes

A number of equities analysts recently weighed in on MDWD shares. HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of MediWound in a report on Friday, January 10th. Craig Hallum assumed coverage on shares of MediWound in a research note on Friday, February 28th. They set a “buy” rating and a $39.00 price target on the stock.

MediWound Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.